Last reviewed · How we verify
ONO-8025 (KRP-197)
ONO-8025 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation.
ONO-8025 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation. Used for Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension.
At a glance
| Generic name | ONO-8025 (KRP-197) |
|---|---|
| Sponsor | Ono Pharmaceutical Co. Ltd |
| Drug class | Prostacyclin analog / IP receptor agonist |
| Target | Prostanoid IP receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
ONO-8025 (also known as KRP-197) is a prostacyclin analog that selectively binds to and activates prostanoid IP receptors. This mechanism leads to increased intracellular cAMP levels, resulting in vasodilation of blood vessels and suppression of platelet activation and aggregation. The drug is being developed for cardiovascular and thrombotic indications where these properties are therapeutically beneficial.
Approved indications
- Pulmonary arterial hypertension
- Chronic thromboembolic pulmonary hypertension
Common side effects
- Headache
- Diarrhea
- Nausea
- Flushing
- Jaw pain
Key clinical trials
- Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan (PHASE2)
- Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan (PHASE3)
- Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ONO-8025 (KRP-197) CI brief — competitive landscape report
- ONO-8025 (KRP-197) updates RSS · CI watch RSS
- Ono Pharmaceutical Co. Ltd portfolio CI